Drug combination may be highly effective in recurrent ovarian cancer

Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer has been identified by recent research. The trial compared the activity of the combination of the drug olaparib, which blocks DNA repair, and the blood vessel inhibitor drug cediranib, vs. olaparib alone. Trial results showed a near doubling of progression-free survival benefit for the combination therapy over use of the single drug alone.